Select Language
CCR8
CCR8 Overview
| English Name | C-C chemokine receptor type 8 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 21 | Target Synonym | Chemokine (C-C) Receptor 8，CC Chemokine Receptor 8，CDw198 Antigen，C-C CKR-8，CC-CKR-8，CCR-8，CMKBRL2，C-C Motif Chemokine Receptor 8，CC chemokine receptor CHEMR1，C-C chemokine receptor type 8，Chemokine (C-C Motif) Receptor 8，C-C Chemokine Receptor Type 8，CC Chemokine Receptor CHEMR1，Chemokine Receptor-Like 1，Chemokine (C-C) Receptor-Like 2，CC-Chemokine Receptor Chemr1，CD_antigen=CDw198，Chemokine receptor-like 1，CKRL1，CKR-L1，CMKBR8，GPRCY6，GPR-CY6，TER1，CDw198，CY6 |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | C-C chemokine receptor type 8 |
| Target Synonym | Chemokine (C-C) Receptor 8，CC Chemokine Receptor 8，CDw198 Antigen，C-C CKR-8，CC-CKR-8，CCR-8，CMKBRL2，C-C Motif Chemokine Receptor 8，CC chemokine receptor CHEMR1，C-C chemokine receptor type 8，Chemokine (C-C Motif) Receptor 8，C-C Chemokine Receptor Type 8，CC Chemokine Receptor CHEMR1，Chemokine Receptor-Like 1，Chemokine (C-C) Receptor-Like 2，CC-Chemokine Receptor Chemr1，CD_antigen=CDw198，Chemokine receptor-like 1，CKRL1，CKR-L1，CMKBR8，GPRCY6，GPR-CY6，TER1，CDw198，CY6 |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 21 |
| Highest Development Stage | Phase 3 Clinical |
CCR8 Product List
- Product Category
Protein (8)Cell (1)Antibody (1)
- Product Status
Launched (10)
- Species
Human (7)Mouse (2)Rhesus macaque (1)
- Tag
His Tag & Flag Tag (1)- (7)Flag Tag & His Tag & Strep Tag (2)
- Conjugate
Unconjugated (7)- (1)Biotin-labeled (2)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT CC8-H52D6 |  Human | HEK293 | Human CCR8 Protein, Flag,His Tag&Twin-Strep Tag (Detergent) |  |  Add to Cart | ||
HOT CC8-H52D7 | Human | HEK293 | Human CCR8 Protein, Flag,His Tag&Twin-Strep Tag (Nanodisc) | | Add to Cart | ||
CC8-H52D3 | Human | HEK293 | Human CCR8 Full Length Protein, Flag,His Tag (Nanodisc-pro) |  | | Add to Cart | |
CC8-H52P5 | Human | HEK293 | Human CCR8 Protein (VLP) | | Add to Cart | ||
CC8-H82D3 | Human | HEK293 | Biotinylated Human CCR8 Protein, His,Flag Tag&Avitag™ (Detergent) | | Add to Cart | ||
CC8-H82D4 | Human | HEK293 | Biotinylated Human CCR8 Protein, His,Flag&Avitag™ (Nanodisc) | | Add to Cart | ||
CHEK-ATP140 | Human | HEK293 | HEK293/Human CCR8 Stable Cell Line |  | Add to Cart | ||
CC8-M52P3 |  Mouse | HEK293 | Mouse CCR8 Full Length Protein (VLP) | Add to Cart | |||
CC8-MY2406 | Mouse | HEK293 | Monoclonal Anti-Human CCR8 Antibody, Mouse IgG2a (11C4C1) (MALS verified) | | Add to Cart | ||
CC8-R52P3 |  Rhesus macaque | HEK293 | Rhesus macaque CCR8 Full Length Protein (VLP) | | Add to Cart |
Total: 10
- 1
CCR8 Background
CCR8 is a G protein-coupled chemokine receptor expressed on regulatory T cells and in tumor microenvironments, mediating chemotaxis, immune regulation, and pathological processes like inflammation or cancer progression. The unconjugated anti-human CCR8 antibody enables specific detection of human CCR8.
CCR8 Synonyms
CC chemokine receptor 8,CDw198,ChemR1,CKRL1,CKR-L1,CKRL1,CY6,GPRCL1,GPRCY6,GPR-CY6,TER-1
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| CCR8 mAb - 01 | PCC | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
| CCR8 mAb - 02 | Lead | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
| CCR8 mAb - 03 | PCC | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
Project Cooperation
| Project Name | Drug Type | Therapeutic Area | Indication | Stage | Rights Area |
|---|---|---|---|---|---|
| CCR8 Humanized Antibody | Bispecific antibody | Oncology/Cancer | Solid Tumor | Preclinical | Global |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Cafelkibart | LM-108 | Phase 3 Clinical | LaNova Medicines Ltd | Carcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Imzokitug | BMS-986340; ONO-7427 | Phase 2 Clinical | Eeig Bristol-Myers Squibb Manufacturing Company Bristol-Myers Squibb Srl | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| TAK- 188 | TAK- 188 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Solid tumours | Details |
| QLP2117 | QLP2117; QLP-2117 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| DT-7012 | DT-7012 | Phase 2 Clinical | Domain Therapeutics SA | Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Neoplasms; Sezary Syndrome; Solid tumours | Details |
| S-531011 | S-531011 | Phase 2 Clinical | Shionogi Inc | Solid tumours | Details |
| IPG-7236 | IPG-7236 | Phase 2 Clinical | Nanjing Immunophage Biotech Co Ltd | Breast Neoplasms; Dermatitis, Atopic; Solid tumours | Details |
| anti-CCR8 antibody (Bristol-Myers Squibb) | Phase 1 Clinical | Bristol-Myers Squibb Company | Solid tumours | Details | |
| PSB-114 | PSB-114 | Phase 1 Clinical | Qilu Puget Sound Biotherapeutics Corp | Neoplasms | Details |
| BAY-3375968 | BAY-3375968 | Phase 1 Clinical | Bayer AG | Neoplasms; Solid tumours | Details |
| ICP-B05 | ICPB05; CM-369 | Phase 1 Clinical | InnoCare Pharma Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Solid tumours | Details |
| HBM-1022 | HBM-1022 | Phase 1 Clinical | Harbour Biomed | Neoplasms | Details |
| Denikitug | JTX-1811; GS-1811 | Phase 1 Clinical | Jounce Therapeutics Inc | Solid tumours | Details |
| Tagmokitug | CHS-114; SRF-114 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| TQB-6457 | TQB-6457; TQB6457 | Phase 1 Clinical | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co Ltd | Neoplasms | Details |
| KYS-2301 | KYS2301; KYS-2301 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Dermatitis, Atopic | Details |
| AMG-355 | AMG 355; AMG-355 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| HC-006 | HC-006; HC006 | Phase 1 Clinical | Shanghai Hongcheng Pharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| BGB-A3055 | BGB-A3055 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
| ABBV-514 | ABBV-514 | Phase 1 Clinical | Abbvie Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Ovarian Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| IPGA-05 | IPGA-05; IPG0521; IPG-0521 | Phase 1 Clinical | Nanjing Immunophage Biotech Co Ltd | Autoimmune Diseases; Immunoglobulin G4-Related Disease; Solid tumours | Details |
- Overview
- Product List
- Clinical Drug Information
Share to: